Background
Methods
Tissue samples
Immunohistochemistry
Results
Clinical and morphologic findings of NLPHL + DLBCL composite lymphomas
NLPHL-DLBCL (n = 33) | Conventional DLBCL (n = 41) | |
---|---|---|
Patients with simultaneous involvement by NLPHL and DLBCL
|
26
|
-
|
Patients with sequential involvement by NLPHL and DLBCL
|
7
|
-
|
Median patient age
(range)
|
50
(19–
78)
|
69
(19–
93)
|
male gender (%)
|
85
|
100*
|
Biopsy site
| ||
- axillary
|
12
(36%)
|
4
(10%)
|
- cervical/
supraclavicular
|
9
(27%)
|
26
(63%)
|
- abdominal/
mesenteric LN
/bowel
|
8
(24%)
|
5
(12%)
|
- inguinal
|
4
(12%)
|
1
(2%)
|
- mediastinal/
retroperitoneal
|
0
|
3
(7%)
|
- other
|
0
|
2
(5%)
|
Splenic involvement
|
30%
|
5%
|
Stage**
| ||
- I
|
2
(9%)
|
7
(17%)
|
- II
|
4
(18%)
|
12
(29%)
|
- III
|
6
(27%)
|
12
(29%)
|
- IV
|
10
(45%)
|
10
(24%)
|
Morphologic findings of NLPHL + DLBCL composite lymphomas
Immunophenotype of NLPHL + DLBCL composite lymphomas
Immuno-staining | DLBCL component positive | LP cells positive | Reduced expression in DLBCL component | Enhanced expression in DLBCL component | Identical expression in DLBCL and NLPHL component | Identical expression in DLBCL and NLPHL in simultaneous cases |
---|---|---|---|---|---|---|
Bcl6 | 33/33 (100%) | 33/33 (100%) | 3% | 0% | 97% | 96% |
CD79a | 33/33 (100%) | 33/33 (100%) | 0% | 33% | 67% | 62% |
CD19 | 32/33 (97%) | 25/32 (78%) | 3% | 66% | 31% | 32% |
CD75 | 31/33 (94%) | 32/33 (97%) | 12% | 9% | 79% | 81% |
EMA | 24/33 (73%) | 27/33 (82%) | 18% | 6% | 76% | 85% |
J-chain | 24/33 (73%) | 27/33 (82%) | 27% | 3% | 70% | 77% |
Bcl2* | 20/32 (63%) | 27/33 (82%) | 0% | 38% | 63% | 69% |
MUM1 | 21/33 (63%) | 24/32 (72%) | 13% | 13% | 75% | 77% |
JAK2 | 12/30 (40%) | 4/27 (15%) | 0% | 23% | 77% | 82% |
CD10 | 12/33 (36%) | 2/33 (6%) | 0% | 33% | 67% | 69% |
p-STAT6 | 9/30 (30%) | 8/26 (31%) | 9% | 5% | 86% | 89% |
CD30 | 7/33 (21%) | 7/33 (21%) | 6% | 6% | 88% | 92% |
CD15 | 4/33 (12%) | 2/33 (6%) | 0% | 12% | 88% | 85% |
IgD | 4/33 (12%) | 5/33 (15%) | 3% | 0% | 97% | 96% |
Independent series of conventional DLBCL
Staining pattern typically observed in DLBCL transformed from NLPHL | “LP type” DLBCL (n = 33) | Conventional DLBCL (n = 41) |
---|---|---|
Bcl-6 strongly positive | 33 (100%) | 34 (83%) |
CD10 weakly or strongly positive | 12 (36%) | 15 (37%) |
CD75 weakly or strongly positive | 31 (94%) | 35 (85%) |
EMA weakly or strongly positive |
24
(73%)*
|
11
(27%)*
|
MUM1 weakly or strongly positive | 21 (63%) | 34 (83%) |
J-chain weakly or strongly positive |
24
(73%)*
|
9
(22%)*
|
Bcl2 weakly positive or negative |
20
(63%)*
|
13
(32%)*
|
CD21-positive follicular dendritic cells | 1/28 (4%) | 5/28 (18%) |
CD23-positive follicular dendritic cells | 0/28 (0%) | 5/28 (18%) |